MA42963A - Préparation pharmaceutique anti-vieillissement - Google Patents

Préparation pharmaceutique anti-vieillissement

Info

Publication number
MA42963A
MA42963A MA042963A MA42963A MA42963A MA 42963 A MA42963 A MA 42963A MA 042963 A MA042963 A MA 042963A MA 42963 A MA42963 A MA 42963A MA 42963 A MA42963 A MA 42963A
Authority
MA
Morocco
Prior art keywords
pharmaceutical preparation
aging pharmaceutical
aging
preparation
pharmaceutical
Prior art date
Application number
MA042963A
Other languages
English (en)
Inventor
Julio Reinecke
Peter Wehling
Original Assignee
Orthogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2016/001888 external-priority patent/WO2017080669A1/fr
Application filed by Orthogen Ag filed Critical Orthogen Ag
Publication of MA42963A publication Critical patent/MA42963A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
MA042963A 2016-08-17 2017-05-11 Préparation pharmaceutique anti-vieillissement MA42963A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16001807 2016-08-17
PCT/EP2016/001888 WO2017080669A1 (fr) 2015-11-13 2016-11-14 Préparation pharmaceutique efficace contre les troubles liés au vieillissement
PCT/EP2016/001887 WO2017080668A1 (fr) 2015-11-13 2016-11-14 Préparation pharmaceutique efficace contre les troubles liés au vieillissement

Publications (1)

Publication Number Publication Date
MA42963A true MA42963A (fr) 2018-08-01

Family

ID=61196401

Family Applications (2)

Application Number Title Priority Date Filing Date
MA042963A MA42963A (fr) 2016-08-17 2017-05-11 Préparation pharmaceutique anti-vieillissement
MA042964A MA42964A (fr) 2016-08-17 2017-05-12 Préparation pharmaceutique anti-vieillissement

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA042964A MA42964A (fr) 2016-08-17 2017-05-12 Préparation pharmaceutique anti-vieillissement

Country Status (21)

Country Link
US (3) US20190290689A1 (fr)
EP (4) EP3352769A1 (fr)
JP (2) JP2019528281A (fr)
KR (2) KR20190049690A (fr)
CN (2) CN108348548A (fr)
AU (2) AU2017313163B2 (fr)
BR (1) BR112019002982A2 (fr)
CA (2) CA3033045A1 (fr)
CL (2) CL2019000420A1 (fr)
CO (2) CO2019001232A2 (fr)
CR (2) CR20190139A (fr)
EA (2) EA201890841A1 (fr)
HK (3) HK1258712A1 (fr)
IL (2) IL259007B2 (fr)
MA (2) MA42963A (fr)
MX (2) MX2019001948A (fr)
PE (2) PE20190627A1 (fr)
PH (2) PH12019550017A1 (fr)
SG (2) SG11201900866YA (fr)
TW (2) TW201806606A (fr)
WO (3) WO2018033226A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528281A (ja) * 2016-08-17 2019-10-10 オアトゲン アクチエンゲゼルシャフトORTHOGEN Aktiengesellschaft 加齢防止製剤
CN108841784A (zh) * 2018-07-17 2018-11-20 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 一种含黄芪甲苷的髓核细胞抗衰老抗凋亡培养基
EP3613424A1 (fr) * 2018-08-23 2020-02-26 Orthogen AG Nouveaux procédés pour la production d'agents pharmaceutiques
RU2695264C1 (ru) * 2018-12-27 2019-07-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Хакасский государственный университет им. Н.Ф. Катанова" (ФГБОУ ВО ХГУ им. Н.Ф. Катанова) Способ прогнозирования ускоренного старения организма женщин, основанный на клинических данных о состоянии репродуктивной функции
SG11202105579VA (en) * 2018-12-27 2021-07-29 Suntory Holdings Ltd Agent for inhibiting reduction in decomposition of denatured elastin, agent for maintaining normal elastin fibers, agent for inhibiting formation of elastin-elafine composite, and screening method for substance having elastin-elafine composite formation inhibitory effect
EP3845566A1 (fr) 2019-12-30 2021-07-07 Industrial Technology Research Institute Procede de separation de vesicules extracellulaires, particule colloidale et procede de preparation de celle-ci
US12077780B2 (en) 2020-02-14 2024-09-03 Allergan Sales, Llc Conditioned medium from cells cultured under hypoxic conditions and uses thereof
TWI911948B (zh) * 2022-05-16 2026-01-11 台灣粒線體應用技術股份有限公司 含粒線體及細胞分泌物的組合物、其用途及其製備方法
JP7624256B1 (ja) * 2024-01-26 2025-01-30 万里 坂井 医薬組成物及びその製造方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007529A2 (fr) * 2004-07-01 2006-01-19 University Of Pittsburgh Of The Commonwealth System For Higher Education Exosomes immunosuppresseurs
DE102006005016A1 (de) * 2006-02-03 2007-08-16 Orthogen Ag Konditionierte Blutzusammensetzung und Verfahren zu deren Herstellung
DE202009017772U1 (de) * 2009-12-10 2011-04-21 Orthogen Ag Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
WO2012076193A1 (fr) * 2010-12-10 2012-06-14 Orthogen Ag Préparations combinées contenant des exosomes et un corticostéroïde
EP3563859B1 (fr) * 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Exosomes dérivés de cardiosphères pour la régénération de tissus
DE102012019088A1 (de) * 2012-09-28 2014-04-03 Orthogen Ag Antibakterielle Arzneimittelpräparate
CN103767985A (zh) * 2012-10-22 2014-05-07 吉林省霍普金斯药物研究院有限责任公司 人源血液或间充质干细胞分泌exosome的制备与应用
KR101784050B1 (ko) * 2014-12-23 2017-10-10 영남대학교 산학협력단 엑소솜을 유효성분으로 함유하는 피부 노화 예방 또는 치료용 약학조성물
WO2017080668A1 (fr) * 2015-11-13 2017-05-18 Orthogen Ag Préparation pharmaceutique efficace contre les troubles liés au vieillissement
CN105477016A (zh) * 2015-11-13 2016-04-13 中国人民解放军第二军医大学 人间充质干细胞来源的外泌体在抗组织纤维化及瘢痕形成中的应用
CN105505854B (zh) * 2016-01-14 2019-07-12 上海市第六人民医院 来源于人尿液细胞的外泌体的获取方法与应用
CN105582576B (zh) * 2016-02-23 2018-08-17 武汉大复生物科技有限公司 提高内皮祖细胞外泌体释放并促进骨缺损修复的生物材料、制备方法及用途
JP2019528281A (ja) * 2016-08-17 2019-10-10 オアトゲン アクチエンゲゼルシャフトORTHOGEN Aktiengesellschaft 加齢防止製剤

Also Published As

Publication number Publication date
EA201890841A1 (ru) 2018-09-28
JP2019528281A (ja) 2019-10-10
EP3763377A1 (fr) 2021-01-13
PH12019550017A1 (en) 2019-11-04
TW201806605A (zh) 2018-03-01
AU2017313164A1 (en) 2018-05-10
TW201806606A (zh) 2018-03-01
IL259007B2 (en) 2024-07-01
SG11201900866YA (en) 2019-02-27
AU2017313164B2 (en) 2019-01-03
IL259007A (en) 2018-07-31
CA3033899A1 (fr) 2018-02-22
JP2019529357A (ja) 2019-10-17
EP3352770A1 (fr) 2018-08-01
EP3695845A1 (fr) 2020-08-19
BR112019002080A2 (pt) 2019-05-14
US20210290671A1 (en) 2021-09-23
MA42964A (fr) 2018-08-01
WO2018033227A1 (fr) 2018-02-22
PH12019550022A1 (en) 2019-12-02
CA3033045A1 (fr) 2018-02-22
IL259006A (en) 2018-07-31
EA201890840A1 (ru) 2018-09-28
CL2019000420A1 (es) 2019-07-05
WO2018033226A1 (fr) 2018-02-22
CR20190091A (es) 2019-05-07
HK1255619A1 (zh) 2019-08-23
PE20190517A1 (es) 2019-04-10
US20190290689A1 (en) 2019-09-26
AU2017313163B2 (en) 2019-01-03
EP3352769A1 (fr) 2018-08-01
CO2019001232A2 (es) 2019-02-28
WO2018033227A8 (fr) 2019-01-24
HK1258712A1 (zh) 2019-11-15
KR20190049690A (ko) 2019-05-09
HK1259143A1 (zh) 2019-11-29
CN108348549A (zh) 2018-07-31
MX2019001948A (es) 2019-05-15
WO2018033249A1 (fr) 2018-02-22
IL259007B1 (en) 2024-03-01
AU2017313163A1 (en) 2018-05-10
CR20190139A (es) 2019-06-03
US20190231816A1 (en) 2019-08-01
PE20190627A1 (es) 2019-04-26
BR112019002982A2 (pt) 2019-05-14
CO2019001265A2 (es) 2019-02-28
KR20190046793A (ko) 2019-05-07
CL2019000419A1 (es) 2019-07-05
MX2019001949A (es) 2019-05-15
CN108348548A (zh) 2018-07-31
SG11201901085RA (en) 2019-03-28

Similar Documents

Publication Publication Date Title
IL290823A (en) Pharmaceutical compositions for combination therapy
IL282304A (en) Topical pharmaceutical compositions
EP3493799A4 (fr) Composition pharmaceutique decannabis
EP3493798A4 (fr) Composition pharmaceutique decannabis
DK3529248T3 (da) Farmaceutiske sammensætninger
HUE054344T2 (hu) Gyógyászati készítmények AZD9291 tartalommal
PL4070788T3 (pl) Formulacje farmaceutyczne
MA42964A (fr) Préparation pharmaceutique anti-vieillissement
MA43705A (fr) Formulation pharmaceutique
DK3529240T3 (da) Farmaceutiske forbindelser
DK3199161T3 (da) Farmaceutisk præparat
EP3603642A4 (fr) Préparation pharmaceutique
EP3452075A4 (fr) Composition pharmaceutique ophtalmique
DK3634377T3 (da) Farmaceutisk formulering
EP3402470A4 (fr) Composition pharmaceutique stable
MA47516A (fr) Composition pharmaceutique
EP3383371A4 (fr) Formulation pharmaceutique
EP3646866A4 (fr) Préparation pharmaceutique
EP3459369A4 (fr) Composition pharmaceutique utilisant la souchelactobacillus
DK3280447T3 (da) Farmaceutiske formuleringer
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
EP3646863A4 (fr) Composition pharmaceutique
EP3646867A4 (fr) Composition pharmaceutique
EP3524250A4 (fr) Composition pharmaceutique
EP3424509A4 (fr) Préparation pharmaceutique liquide